Disease tolerance can preserve host homeostasis and limit the negative impact of infections. We report that vaccinated mice survived pulmonary challenge with the extremely virulent SchuS4 strain of Francisella tularensis for at least 100 days, despite the persistence of large numbers (~10 4 ) of organisms. Transfer of 100 of these resident bacteria to naive animals caused 100% lethality, demonstrating that virulence was maintained. Tissue damage in the lung was limited over the course of infection and was associated with increased levels of amphiregulin. Mice depleted of CD4 + cells had reduced amphiregulin and succumbed to infection. In addition, neutralization of interferon-γ or depletion of CD8 + cells resulted in increased pathogen loads, bacteremia, and death of the host. Conversely, depletion of Ly6G + neutrophils had no effect on survival and actually resulted in reduced bacterial levels. Understanding the interplay between host resistance and disease tolerance will provide new insights into the understanding of chronic infectious diseases.
Traditionally, survival from infectious disease has been thought to depend on the ability of the host to kill and clear the invading pathogen. Host resistance reduces pathogen burden once the infection is established; however, pathogen clearance mechanisms can also result in extensive damage to host tissue. Disease tolerance can reduce the negative impact of infection without directly affecting levels of pathogen burden [1, 2] . Thus, while host survival is typically framed within the construct of pathogen clearance, disease tolerance in the absence of sterilizing immunity can also be an important contributor to the maintenance of host health. Resistance and disease tolerance can operate simultaneously, wherein host resistance mechanisms maintain a manageable burden level and disease tolerance mechanisms protect the host from destructive tissue damage.
One mechanism responsible for disease tolerance is the tissue repair response [3, 4] . Some tolerance mechanisms that maintain tissue integrity include downregulation of Toll-like receptors, activation of the stress response to eliminate reactive oxygen species, and increased type 2 cytokine responses [2] [3] [4] . Amphiregulin, a type 2 cytokine, is a key component for maintenance of disease tolerance, as it promotes the proliferation and survival of epithelial cells following damage associated with inflammation [5] .
We now show that a highly virulent pulmonary pathogen, Francisella tularensis SchuS4, can maintain a chronic infection in vaccinated hosts. The host survives through partial resistance as well as disease tolerance that involves limited tissue damage and increased amphiregulin expression. Our findings may provide novel insight into intracellular bacterial lung infections that are only partially controlled by vaccination attempts.
MATERIALS AND METHODS

Mice and Bacterial Infection
Five-week-old male and female BALB/c mice were purchased from Charles River Laboratories and The Jackson Laboratory. Mice were housed at Albany Medical College and all procedures were approved by the Institutional Animal Care and Use Committee. For vaccination, mice were anesthetized by intraperitoneal injection of 20 mg/mL xylazine and 1 mg/ mL ketamine, and were inoculated intranasally with 40 µL phosphate-buffered saline (PBS) containing 50 colony-forming units (CFU) of F. tularensis live vaccine strain (LVS). For respiratory challenge, anesthetized mice were infected intranasally with 40 µL PBS containing 40-100 CFU F. tularensis SchuS4.
Histological Analysis
Lungs were harvested from SchuS4-infected animals, fixed in 10% formalin, and embedded in paraffin. Sections were stained with hematoxylin and eosin, and visualized using light microscopy (Olympus BX41).
Amphiregulin Measurement
Bronchoalveolar lavage fluid (BALF) was collected by lavaging with 1 mL sterile PBS. Amphiregulin was measured using a cytokine-specific enzyme-linked immunosorbent assay (R&D Systems) per the manufacturer's instructions.
In Vivo Cell Depletion and Cytokine Neutralization
All depleting/neutralizing monoclonal antibodies (mAbs) were obtained from BioXcell. To neutralize IFN-γ, 600 µg of anti-IFN-γ (clone XMG1.2) were administered intraperitoneally every day for 3 consecutive days. To deplete CD4 + or CD8 + cells, 200 µg of anti-CD4 (clone GK1.5) or anti-CD8α (clone 2.43) were administered intraperitoneally every day for 3 consecutive days. To deplete Ly6G + cells, 100 µg of anti-Ly6G (clone 1A8) were administered intraperitoneally every other day for a total of 3 treatments.
Flow Cytometry
For flow cytometric analysis, single-cell suspensions of lung cells were prepared by incubating lung tissue sections in 1 mL of digestion buffer (2 mg/mL collagenase D, 0.25 mg/ mL DNase I, 10mM magnesium chloride in RPMI 1640) for 45 minutes at 37°C. The cell suspensions were then passed through a 40-µm mesh, centrifuged for 5 minutes at 2500g at 4°C, and resuspended in 1% fetal bovine serum in PBS. For intracellular staining experiments, cells were incubated for 2 hours at 37°C with 2 µL/mL PMA Cell Activation Cocktail (BioLegend). Fc receptors were blocked with 2.4G2 antimouse FcγII/III receptor mAb for 15 minutes at 4°C, and the cells were washed and incubated with cell subset-specific mAb diluted in blocking buffer for 30 minutes at 4°C. The mAb used were fluorescein isothiocyanate (FITC)-conjugated anti-CD4 (clone GK1.5, 1:200, BioLegend), PerCP efluor 710-conjugated antiNKp46 (clone 29A1.4, 1:200, eBioscience), allophycocyanin (APC)-conjugated anti-CD3 (clone 17A2, 1:200, BioLegend), phycoerythrin-conjugated anti-CD8 (clone 53-6.7, 1:100, BD Bioscience), FITC-conjugated anti-Gr1 (clone RB6-8C5, 1:200, BioLegend), and PerCP Cy5.5-conjugated anti-F4/80 (clone BM8, 1:200, eBioScience). After staining surface markers, cells were permeabilized and fixed using BD Cytofix (BD Biosciences) for 20 minutes at 4°C. The cells were then washed and incubated with either APC-conjugated anti-IFN-γ mAb (clone XMG1.2, 1:200, BioLegend) or APC-conjugated isotype control mAb (clone RTK2071, 1:200, BioLegend) for 30 minutes in 1X perm/wash buffer (BD Biosciences) at 4°C. The stained cells were analyzed on a Guava easyCyte 6HT-2L flow cytometer. Data were analyzed using FlowJo software.
Statistical Analysis
Bacterial clearance, cytokine production, and total cell numbers were analyzed by a ROUT test to identify potential outliers. Following this test, the data were analyzed by either a Student t test or analysis of variance followed by Tukey multiple comparisons tests. Only corrected P values are reported in the text. Survival analyses used the Mantel-Cox log-rank test. Statistical procedures were performed using GraphPad Prism 7 software. Each graph shows means ± standard deviations. P values of < .05 were considered to be statistically significant.
RESULTS
Vaccinated BALB/c Mice Develop a Chronic Infection Following
Pulmonary Challenge With Highly Virulent SchuS4 F. tularensis
There are two strains of F. tularensis that most often cause disease in humans. The type A strain, F. tularensis subspecies tularensis (SchuS4), is highly virulent, and a dose as low as 10 CFU can result in lethality if left untreated. The type B strain, F. tularensis subspecies holarctica (LVS), is attenuated and has been previously used for human vaccination. In agreement with other reports [6] [7] [8] , BALB/c mice were fully protected against lethal challenge with 40 CFU of highly virulent F. tularensis SchuS4 following pulmonary vaccination with LVS (Supplementary Figure 1) . However, the surviving mice failed to control bacterial replication, despite remaining healthy. Lung bacterial burdens peaked at about 10 6 -10 7 CFU between days 6 and 8 after SchuS4 challenge, and then remained high (>10 4 per lung) for at least 30 days ( Figure 1A) . A similar trend was observed in the spleen ( Figure 1B) .
Given the high numbers of bacteria that were present after 30 days in vaccinated BALB/c mice surviving SchuS4 infection, we extended analyses to 100 days. Approximately 75% of vaccinated BALB/c mice survived during this period ( Figure 1C ). Interestingly, all mice still had relatively high levels of bacteria (10 2 -10 6 CFU) in their lungs and/or spleens on day 100. Of those mice without detectable lung bacteria, bacteria were present in their spleens, and vice versa ( Figure 1D ).
An intranasal SchuS4 challenge dose of only 10 CFU routinely leads to 100% mortality in naive BALB/c mice; thus, we were astonished to find approximately 10 4 CFU in the lungs of LVSvaccinated, SchuS4-challenged, and apparently healthy animals. To determine whether the bacteria had become less virulent while present in the surviving animals, lung homogenates from either naive or 30-day infected mice were transferred intranasally into either naive or vaccinated BALB/c mice. The homogenates from SchuS4-infected mice were diluted to a concentration of approximately 100 CFU/recipient, that is, approximately 1% of the bacterial levels observed in the donor animals. As expected, all animals that received lung homogenates from naive mice survived, as did LVS-vaccinated mice challenged with 100 CFU of stock SchuS4 (Figure 2A) . Conversely, naive mice that received lung homogenates from challenged and surviving BALB/c mice succumbed in a manner similar to naive mice challenged with stock SchuS4. Interestingly, LVS-vaccinated mice that received lung homogenates from challenged and surviving BALB/c mice were not completely protected and succumbed to infection 3-4 weeks after the homogenate transfer. Polymerase chain reaction (PCR) analysis confirmed that the resident bacteria were indeed SchuS4 and not residual LVS ( Figure 2B ). Moreover, the SchuS4 bacteria present in surviving animals were still susceptible to antibiotic-mediated clearance, including antibiotics that inhibit DNA synthesis (data not shown), indicating that they remained metabolically active. Taken together, these data show that mice acquire disease tolerance to the virulent SchuS4 pathogen following LVS vaccination but do not develop sterilizing immunity.
Survival Correlates With Maintenance of Lung Homeostasis During Chronic SchuS4 Infection
Given the persistence of high bacterial loads in the lungs of infected mice, we considered the possible role of disease tolerance and maintenance of lung integrity in host survival. Thus, we examined the lung tissues of infected mice at various time points after pulmonary SchuS4 infection. BALB/c mice had increased pathology after infection with SchuS4; however, pathological damage remained constant for at least 100 days postinfection (Figure 3A and 3B; P = .9026). Furthermore, amphiregulin protein levels in BALF were significantly increased in chronically infected mice ( Figure 3C ; P < .05). Our data suggest that BALB/c mice survive a chronic lung infection with F. tularensis SchuS4 not by clearing the infection, but by maintaining lung homeostasis, a hallmark of disease tolerance.
CD4 + Cells Are Required for Disease Tolerance and Resistance
Because CD4 + cells are necessary for protection against chronic intracellular pathogens [9, 10], we predicted that CD4 + cells could be pivotal in maintaining disease tolerance to SchuS4. To test this, we treated chronically infected mice with depleting anti-CD4 mAb. Two weeks later, 90% of mice succumbed to infection, whereas the isotype control-treated mice survived. This demonstrates that CD4 + cells were required for protection during chronic SchuS4 infection ( Figure 4A ; P < .01). In agreement with decreased survival in CD4-depleted mice, there was a significant increase in bacterial burden in the lungs, suggesting that these cells play a role in maintaining resistance ( Figure 4B ; P < .01). Furthermore, while bacteria were undetectable in the blood of isotype-treated mice, anti-CD4 mAb treatment resulted in significant levels of bacteremia ( Figure 4C ; P < .0001). T cells have been shown to be a potential source of amphiregulin in various models [5, [11] [12] [13] . Following CD4 depletion, amphiregulin levels were significantly decreased, indicating that these cells contribute to the production of amphiregulin in chronic SchuS4 infection ( Figure 4D ; P < .05). Taken together, our results show that CD4 + cells are required for resistance and maintaining disease tolerance, possibly by producing amphiregulin and preserving tissue integrity to prevent disseminated infection. 
SchuS4 Infection Recruits Ly6G hi Cells to the Lungs of
Chronically Infected Mice
We next characterized the pulmonary immune cells in chronically infected mice. Compared to mock-infected mice, chronically infected mice had a noticeable increase in a Ly6C int Ly6G hi CD11b + subset of cells, a phenotype typically associated with neutrophils [14, 15] (Figure 5A and Supplementary Figure 2) . A similar trend was seen in the spleens (data not shown). Furthermore, histological analysis of lungs from chronically infected mice showed a predominance of polymorphonuclear cells ( Figure 5B) .
We next explored the importance of neutrophils during chronic SchuS4 infection in vaccinated animals. Infected mice were treated with an anti-Ly6G mAb and were monitored for survival. Depletion was confirmed by flow cytometric analysis (Supplementary Figure 3) . Mice depleted of Ly6G + cells remained healthy for at least 30 days following treatment (Figures 5C). Thus neutrophils were not necessary for survival during chronic SchuS4 infection.
We also evaluated bacterial burdens in the anti-Ly6G-treated mice. Incredibly, mice treated with anti-Ly6G mAb had undetectable bacteria in their lungs, and significantly fewer bacteria in the spleen compared with isotype control-treated mice (Figures 5D). These data suggest that neutrophils inhibit bacterial clearance in chronically infected mice. Analysis of bacterial burdens in enriched neutrophil populations showed that Ly6G + cells harbored substantial amounts of SchuS4 bacteria (Supplementary Figure 4) .
IFN-γ Is Necessary for Survival During Chronic SchuS4 Infection
It is well known that IFN-γ is required for protection against infection with attenuated F. tularensis LVS and, in vaccinated animals, acute infection with SchuS4 [16] [17] [18] [19] [20] . During chronic SchuS4 infection, we observed elevated levels of lung IFN-γ compared with mock-infected mice ( Figure 6A ). Therefore, we tested whether IFN-γ was necessary for continued disease tolerance and survival during chronic SchuS4 infection. Treatment with anti-IFN-γ mAb caused chronically infected mice to succumb to infection, whereas isotype control-treated mice survived, demonstrating that IFN-γ was absolutely required for ongoing protection during chronic SchuS4 infection ( Figure 6B ). Despite decreased survival in IFN-γ-neutralized mice, there was only a small, but not statistically significant, change in bacterial burden in the lungs and spleens ( Figure 6C ). 
, open triangles) or isotype control (closed circles) monoclonal antibody (mAb) 3 weeks after Francisella tularensis
SchuS4 infection (4-9 mice/group, combined from 2 independent experiments). **P < .01 as determined by Mantel-Cox log-rank test. Bacterial burdens in the lungs (B) and blood (C) 8 days after anti-CD4 or isotype control mAb treatment (6-8 mice/group, combined from 2 independent experiments). Limit of detection was 10 colony-forming units (CFU). **P < .01; ****P < .0001 as determined by Student t test. D, Amphiregulin levels in the bronchoalveolar lavage fluid (BALF) from mice 8 days after the last treatment of either anti-CD4 or isotype control mAb (5-7 mice/group, combined from 2 independent experiments). *P < .05 as determined by Student t test.
Notably, while bacteria were undetectable in the blood of isotype control-treated mice, there were significant numbers of bacteria in the blood of IFN-γ-neutralized mice ( Figure 6D ). These results show that IFN-γ is required for maintaining longterm protection during chronic F. tularensis SchuS4 infection, likely by limiting bacterial dissemination into the blood.
CD8 + Cells Are Required for Protection Against Chronic SchuS4
Infection
We next evaluated the cells that expressed IFN-γ during chronic SchuS4 infection. While various cell populations expressed IFN-γ, we saw a substantial increase in numbers of IFN-γ + CD8 + T cells ( Figure 7A and Supplementary Figure 5) . We thus tested if CD8 + cells were required for survival during chronic SchuS4 infection. It was found that CD8-depleted mice succumbed to infection ( Figure 7B ). Additionally, mice treated with anti-CD8 mAb had increased bacterial burdens in their lungs and spleens, compared with isotype-treated control mice ( Figure 7C ). Similar to anti-IFN-γ treatment, mice treated with anti-CD8 mAb contained significant numbers of bacteria in the blood ( Figure 7D ). These results show that CD8 + cells play a critical role in maintaining long-term protection during chronic SchuS4 infection. This likely involved production of IFN-γ and limiting development of bacteremia.
DISCUSSION
We found that although vaccinated BALB/c mice survived SchuS4 pneumonic tularemia, they continued to harbor significant numbers of highly virulent bacteria in their lungs and peripheral organs for at least 100 days following challenge. Surprisingly, despite this chronic infection, there was no increase in lung pathology over time. Tissue integrity correlated with an increase in amphiregulin production, whereas depletion of CD4 + cells resulted in increased bacterial burden in the lungs and blood as well as decreased amphiregulin in the BALF. Additionally, Ly6G hi cells were recruited to the lungs of chronically infected mice and harbored bacteria. Long-term host resistance to lethal infection also required IFN-γ expression and CD8 + cells. Our results show that although vaccination allowed survival following highly virulent pathogen challenge, it did not result in sterilizing immunity. As fully virulent bacteria or isotype control mAb treatment (6-9 mice/group, combined from 2 independent experiments). Limit of detection was 10 colony-forming units. **P < .01; ****P < .0001 as determined by 2-way analysis of variance followed by Tukey multiple comparisons test. Abbreviations: ns, not significant.
remained, a subsequent immunocompromised state led to bacterial dissemination and development of lethal infection. Although pneumonic tularemia is generally considered to be an acute infection, we found that all surviving mice still contained bacteria as late as 100 days after challenge, and at numbers much higher than the dose necessary to kill naive mice (~10 CFU). Overall burden in the spleen was lower than the burden in the lungs, suggesting that the host attempts to contain the bacteria in the lung to avoid sepsis. In mice where bacteria were not found in the lungs, it is likely that bacteria were still present, but below the limit of detection. No bacteria were found in the brain (unpublished observation). The bacteria were still highly virulent, as shown by adoptive transfer of lung homogenates into naive mice. It is possible that bacteria in chronically infected mice were more virulent than stock SchuS4, and/or transferred homogenates could have contained host factors that influenced survival in the vaccinated recipient. PCR analysis demonstrated that the bacteria were SchuS4 rather than residual LVS. Moreover, the remaining bacteria could be eliminated from the lungs and spleen with levofloxacin treatment; after this treatment, the animals developed resistance to a secondary SchuS4 challenge (unpublished observations).
Our results show that F. tularensis can cause a subclinical, latent infection that may ultimately escape host resistance and disease tolerance. This is similar to other intracellular bacteria that grow within lung phagocytes, such as Mycobacterium tuberculosis, Listeria monocytogenes, and Burkholderia mallei [21] [22] [23] . While at least two studies detected type A F. tularensis (~10 4 CFU) in the lungs and spleens of vaccinated mice [8, 24] , the surviving animals were studied for relatively short periods of time and development of long-term chronic infection was not investigated. Of significant interest, very early clinical studies described infected patients that still harbored bacteria months after treatment, and at least one patient experienced serious relapse 9 months after the initial infection [25] . Similarly, various case reports have shown that F. tularensis infection can appear unexpectedly in immunocompromised humans [26] . Notwithstanding these early reports, the field still widely considers F. tularensis to be a pathogen that only causes acute infection. Perhaps due to the lack of recognition of a chronic phase of infection, development of effective vaccination strategies against F. tularensis, like those for other intracellular lung pathogens, has been extremely challenging.
Despite being chronically infected with a highly virulent pathogen, the mice in our study maintained their lung tissue integrity for at least 100 days. Furthermore, chronically infected animals had increased amphiregulin protein in their BALF. There was no noticeable association between histopathology/ amphiregulin and burden levels. However, amphiregulin is a key component during disease tolerance, as it promotes the proliferation and survival of epithelial cells following damage associated with inflammation [5] . Various studies have characterized the importance of amphiregulin in viral infections [5, 11-13, 27, 28] , but little is known about its role in bacterial infections. Depletion of CD4 + cells during chronic SchuS4 infection resulted in decreased survival, increased bacterial burden, decreased amphiregulin levels, and dissemination of bacteria into the blood. Therefore, CD4 + cells are important for protection during chronic SchuS4 infection, possibly by maintaining both host resistance and disease tolerance. We found that after SchuS4 infection, Ly6G + cells were recruited to the lungs. Depletion of these cells had no effect on survival but actually resulted in clearance of the bacteria from the lung. The precise role of neutrophils in either host resistance or disease tolerance to the virulent bacteria is currently being investigated, but we can conclude that neutrophils played an important role in maintaining bacterial burden levels in the infected mice. It is known that F. tularensis infection can increase neutrophil survival [29] , and we found that these cells can harbor bacteria in chronically infected mice. We suspect that F. tularensis can evade neutrophil killing similar to how it escapes the phagolysosome in the macrophage [30] . We saw that other cells also contained viable bacteria. We hypothesize that neutrophils inhibit clearance of bacteria from these other cells, which would likely include macrophages. In agreement with our data demonstrating an important role for neutrophils in supporting bacterial growth, recent studies have shown that neutrophils exacerbate infection with M. tuberculosis [31] [32] [33] [34] . Of note, depletion of either CD4 + or CD8 + cells had no apparent effect on Ly6G + cell populations (unpublished observation).
Neutralization of IFN-γ in apparently healthy, chronically infected animals led to dissemination of the bacteria into the bloodstream and death of the mice within a few days. A similar requirement for IFN-γ has been reported for protection against acute LVS infection and for effective LVS vaccination against subsequent SchuS4 challenge [16-19, 35, 36] . Despite the increased levels of IFN-γ following SchuS4 infection, mice still failed to clear the bacteria. Other studies have demonstrated that IFN-γ restricts granulopoiesis [37] and regulates neutrophil recruitment to sites of infection [38, 39] . During M. tuberculosis infection, IFN-γR -/-mice have increased inflammation and neutrophil recruitment to the lungs [40] . Our studies showed that during chronic F. tularensis infection, IFN-γ had an anti-inflammatory function that prevented bacterial dissemination into the bloodstream. We predict that IFN-γ also plays a role in preventing pneumonic tularemia by limiting neutrophil recruitment.
We also found that CD8 + cells were necessary for maintaining survival in chronically infected mice and were the primary source of IFN-γ. Previous studies have shown that development monoclonal antibody (mAb) 3 weeks after SchuS4 infection (4-9 mice/group, combined from 2 independent experiments). **P < .01 as determined by Mantel-Cox log-rank test. Bacterial burdens in the lungs and spleens (C) and blood (D) 8 days after anti-CD8 or isotype control mAb treatment (6-9 mice/group, combined from 2 independent experiments). Limit of detection was 10 colony-forming units (CFU). **** P < 0.0001 as determined by 2-way ANOVA followed by Tukey multiple comparisons test; * P < 0.05 as determined by Student t test.
of effective immunity to SchuS4 during the early stages of LVS vaccination is dependent on CD8 + T cells and, in other infection models, CD8 + T cells are the primary producers of IFN-γ [8, 20, [41] [42] [43] ; thus, our results are not unprecedented. Although some investigators have reported that T cells can control LVS intramacrophage growth during in vitro co-culture [44] , our results indicate that T cells are linked to dissemination rather than direct killing. Interestingly, a recent study demonstrated that expansion of T cells compromises disease tolerance independent of host resistance to M. tuberculosis infection [45] . Despite some procedural limitations working under Biosafety Level 3 conditions, we were able to show that mice surviving SchuS4 pneumonic tularemia following vaccination still contained large numbers of extremely virulent bacteria that caused lethal infection when the animals became immunocompromised. The reason for the lack of sterilizing immunity in surviving mice is currently unknown, but may be related to the ability of F. tularensis to subvert host defense systems [46, 47] . Nevertheless, the infected mice did develop significant levels of anti-F. tularensis serum antibodies and were resistant to a secondary SchuS4 challenge (unpublished observations). Thus, the animals were disease tolerant, but not "immune tolerant" to the pathogen.
Our findings provide new insights into the ability of intracellular bacteria to form persistent lung infections that can ultimately develop into fatal disease. In addition, our results are clearly relevant to development of current [48] and planned tularemia vaccination trials in humans. Nevertheless, it is possible that a more potent vaccine, or one not delivered into the lungs, may overcome the lack of sterilizing immunity seen with LVS. Taken together, our results demonstrate that an infected host can develop disease tolerance to an extremely virulent lung pathogen and that continued survival requires intact host resistance.
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